#PrEP HIV

[fidicushiv]

Call : +917997101303 | Whatsapp : https://wa.me/917997101505 | Website : https://fidicus.com

ఎక్కువ మందితో ప్రొటెక్షన్ లేకుండా కలుస్తున్నారా? Unprotected Sex | HIV AIDS PrEp Treatment Cure

Stay protected from HIV infection even when engaging in sex with multiple unknown partners by using PrEP (Pre-Exposure Prophylaxis) treatment. This YouTube video explains how PrEP effectively reduces the risk of HIV transmission when taken consistently. Learn about the importance of regular medical consultations, proper condom use, and adherence to the medication. Stay informed and safeguard your health with these essential prevention strategies.

Dr. Bharadwaz | HIV AIDS | Health & Fitness | Homeopathy, Medicine & Surgery | Clinical Research

#PrEP #HIVPrevention #SafeSex #SexualHealth #hivawareness

#DrBharadwaz #Helseform #Fidicus #Clingenious

#ClingeniousHealth #HelseformFitness #FidicusHomeopathy #ClingeniousResearch

#FidicusHIV #HIV #AIDS #HumanImmunodeficiencyViruses #AcquiredImmuneDeficiencySyndrome

#Treatment #Cure #Prevent #Relieve #Medicine #Vaccine

#AlternativeTherapy #AdjuvantTherapy #AlternativeMedicine #AlternativeSystem

Specialty Clinic Fidicus HIV highest success with homeopathy Improve Wellness | Increase Longevity | Addresses Questions

[reasonsforhope]

"A large clinical trial in South Africa and Uganda has shown that a twice-yearly injection of a new pre-exposure prophylaxis drug gives young women total protection from HIV infection.

The trial tested whether the six-month injection of lenacapavir would provide better protection against HIV infection than two other drugs, both daily pills. All three medications are pre-exposure prophylaxis (or PrEP) drugs.

Physician-scientist Linda-Gail Bekker, principal investigator for the South African part of the study, tells Nadine Dreyer what makes this breakthough so significant and what to expect next.

Tell us about the trial and what it set out to achieve

The Purpose 1 trial with 5,000 participants took place at three sites in Uganda and 25 sites in South Africa to test the efficacy of lenacapavir and two other drugs.

Lenacapavir (Len LA) is a fusion capside inhibitor. It interferes with the HIV capsid, a protein shell that protects HIV’s genetic material and enzymes needed for replication. It is administered just under the skin, once every six months.

The randomised controlled trial, sponsored by the drug developers Gilead Sciences, tested several things.

The first was whether a six-monthly injection of lenacapavir was safe and would provide better protection against HIV infection as PrEP for women between the ages of 16 and 25 years than Truvada F/TDF, a daily PrEP pill in wide use that has been available for more than a decade.

Secondly, the trial also tested whether Descovy F/TAF, a newer daily pill, was as effective as F/TDF...

The trial had three arms. Young women were randomly assigned to one of the arms in a 2:2:1 ratio (Len LA: F/TAF oral: F/TDF oral) in a double blinded fashion. This means neither the participants nor the researchers knew which treatment participants were receiving until the clinical trial was over.

In eastern and southern Africa, young women are the population who bear the brunt of new HIV infections. They also find a daily PrEP regimen challenging to maintain, for a number of social and structural reasons.

During the randomised phase of the trial none of the 2,134 women who received lenacapavir contracted HIV. There was 100 percent efficiency.

By comparison, 16 of the 1,068 women (or 1.5%) who took Truvada (F/TDF) and 39 of 2,136 (1.8%) who received Descovy (F/TAF) contracted the HIV virus...

What is the significance of these trials?

This breakthrough gives great hope that we have a proven, highly effective prevention tool to protect people from HIV.

There were 1.3 million new HIV infections globally in the past year. Although that’s fewer than the 2 million infections seen in 2010, it is clear that at this rate we are not going to meet the HIV new infection target that UNAIDS set for 2025 (fewer than 500,000 globally) or potentially even the goal to end Aids by 2030...

For young people, the daily decision to take a pill or use a condom or take a pill at the time of sexual intercourse can be very challenging.

HIV scientists and activists hope that young people may find that having to make this “prevention decision” only twice a year may reduce unpredictability and barriers.

For a young woman who struggles to get to an appointment at a clinic in a town or who can’t keep pills without facing stigma or violence, an injection just twice a year is the option that could keep her free of HIV.

What happens now?

The plan is that the Purpose 1 trial will go on but now in an “open label” phase. This means that study participants will be “unblinded”: they will be told whether they have been in the “injectable” or oral TDF or oral TAF groups.

They will be offered the choice of PrEP they would prefer as the trial continues.

A sister trial is also under way: Purpose 2 is being conducted in a number of regions including some sites in Africa among cisgender men, and transgender and nonbinary people who have sex with men.

It’s important to conduct trials among different groups because we have seen differences in effectiveness. Whether the sex is anal or vaginal is important and may have an impact on effectiveness.

How long until the drug is rolled out?

We have read in a Gilead Sciences press statement that within the next couple of months [from July 2024] the company will submit the dossier with all the results to a number of country regulators, particularly the Ugandan and South African regulators.

The World Health Organization will also review the data and may issue recommendations.

We hope then that this new drug will be adopted into WHO and country guidelines.

We also hope we may begin to see the drug being tested in more studies to understand better how to incorporate it into real world settings.

Price is a critical factor to ensure access and distribution in the public sector where it is badly needed.

Gilead Sciences has said it will offer licences to companies that make generic drugs, which is another critical way to get prices down.

In an ideal world, governments will be able to purchase this affordably and it will be offered to all who want it and need protection against HIV."

-via The Conversation, July 3, 2024

[filmnoirsbian]

My cishet brother in law ally of the year. Every time he learns abt some new type of homophobia he's like >:( that's so MEAN why would anyone DO that‼️‼️ He learned abt chick fil a's whole thing and was so outraged. My sister (lifelong vegetarian) came home and he said "Babe we are NEVER going to chick fil a again do you know what they DO?? To gay people??? We CANNOT support that 😡😡"

[creepyscritches]

Formulating a high level question on the financial side of medicine when my strength lies in clinical and only hearing crickets in the call when I finish like.......am I loudly stupid or does no one have an answer

[batsarebetterthanpeople]

""I'm sorry ma'am but it needs to go through a specialty pharmacy"" it is not that hard I just want my bespoke faggot meds so I don't get AIDS goddamn

[fxmmeangel]

twitter keeps showing me posts about how people who take prep are whores?? and like getting aids/hiv is some morally reprehensible act that means you’re awful?? what is wrong with yall 😻

[frameacloud]

Brittney McNamara (December 5, 2016). "What to Do If You've Been Exposed to HIV." Teen Vogue.

The more people who know about what to do in that situation, the better.

[gwydionmisha]

This is something 1988 me couldn't imagine. We've made so much progress.

[puppy-darling]

BTW PrEP is pretty easy to get on in most US states, the most annoying thing about it is that you have to get tested monthly-ish, but also you should be getting tested anyway. All the hot gays are on PrEP. It reduces your chance of acquiring HIV from sex by NINETY NINE PERCENT.

You never know if condoms will tear! Many people don't know their HIV status! You can get HIV from oral sex on any type of genitalia!

ONE pill a day!

Be PrEPared!

[gumjrop]

The Weather

A study in Clinical Infectious Diseases reported “that the risk of developing symptomatic illness within 14 days was 5 times greater when contacts were exposed to an asymptomatic [COVID]-positive child in their household.” Nearly 11% of household contacts developed symptoms within 14 days of exposure. The study also found, during a 3-month follow-up, that 6 out of 77 asymptomatic children developed Long COVID. The likelihood of developing symptoms from asymptomatic exposure is higher than we might expect. Continue to spread awareness of asymptomatic spread and advocate for increased infection control measures at your local schools.

COVID wastewater levels are decreasing. As of 3/29/24, New Mexico is “Very High,” Arkansas and Kentucky are “High,” and the rest of the states are “Moderate” to “Low” levels of SARS-CoV-2 detected in wastewater. 

Wastewater levels continue to show a downward trend in the provisional data (gray shaded area) in all regions. The national wastewater levels are overall indicated as “Low.” While lower wastewater levels indicate decreased spread, it is important to continue to take precautions against infection. Holidays and spring breaks may bring people in closer proximity, so be sure to wear a mask to protect yourself and your community.

Wins

As we work to take more actions against the removal of vital public health measures, we remind you that you can still watch the recording of the People’s CDC press conference from March 13 and read the press release here. We would also like to remind you of the pre-proof of the People’s CDC External Review in the American Journal of Preventive Medicine Focus. The publication highlights the shortcomings of the CDC’s approach to public health and recommends a more equitable pandemic response.

News sources have published articles about the frustrations of people who continue to take COVID precautions. Time Magazine published an article presenting “both sides,” highlighting protest from people working with the CDC and concern from citizens and experts alike. While we are glad to see our voices be published in popular media, we are also saddened that “returning to normal” under economic and political pressure is so valued.

Treatments

Invyvid has received an FDA emergency use authorization for Pemgarda, a pre-exposure prophylaxis (PrEP) for people with immunocompromising conditions. Pemgarda is approved for people 12 and older with moderate to severe immunocompromise who are less likely to produce an adequate immune response to COVID vaccination alone. According to a press release from Invyvid, Pemgarda will release to market “imminently.”

Pre-exposure prophylaxis is commonly used for folks at high risk for exposure to HIV. As access to PrEP for HIV has been instrumental in keeping people safe, we hope that PrEP for COVID will be a useful tool for our community members with immune compromise. We also urge you to continue to wear high-quality masks and take other precautions to protect those most vulnerable.

Long COVID

People Magazine recently published an article highlighting an essay by Ziyad Al-Aly, physician and clinical epidemiologist, that pools data from several studies showing that COVID infection has lasting impacts on brain health. The review points out several impacts to cognitive functioning, including memory loss, spatial reasoning, and planning. Additionally, imaging studies have shown significant impact to brain tissue from inflammation, among other processes. The publication may be validating to those who experience lower cognitive function following COVID infection, including brain fog and memory dysfunction.

Take Action

We know that taking precautions–including masking, testing, and improving air quality–helps prevent the spread of airborne viral infection. Introducing more stringent precautions slowed outbreaks in the hematology ward of a hospital. The CDC recently released tips to improve ventilation. Help us urge the CDC to take other measures, including reinstating isolation periods. 

Additionally, the home Test to Treat program is ending in April 2024. The program provides un-or-underinsured adults with free COVID and flu tests. If a participant in the program tests positive, they can also receive free healthcare via telehealth services. Join us to help save the program that helps so many at-risk people!

[puppyvomits]

Navigating HIV in the age of Sniffies and PREP.

I am HIV neutral. This is a term coined by DogBoiBailey to designate people like us: those living with HIV who are on treatment and undetectable. People who are living with HIV who are on medication and undetectable neutralize the virus' effects on our bodies and are unable to transmit the virus. I have been living with HIV since 2021 and have often discussed that despite my transparency with my status, that I do not believe that any person living with HIV owes disclosure of their status to others at the beginning of an interaction or when you show interest in them. This belief has often times been met with pushback from community members who believe that it is irresponsible to say that people with HIV should have a choice in whether they disclose their status to others. I also recognize that certain states have laws that require disclosure and yet despite this, I assert my belief that upfront disclosure is not owed to anyone. Disclosure laws are rooted in the historic homophobia and stigma that is associated with HIV/AIDS in the United States and was often times used as a means of weaponizing the criminal justice system against marginalized communities who were deemed as "dirty" and "suffering the repercussions of being men who sleep with men". It forced HIV patients in the 80s out to employers in a time where there were no laws protecting people from being fired for their HIV status or sexual orientation. Even today, people who argue that people living with HIV owe others disclosure ignore the very real stigmas associated with HIV and ignore that not all states, cities, and communities accept or treat people living with HIV with understanding or acceptance. On hookup apps, we often see bios that boldly demand you "Be clean" or "disease free". There are tattoo artists who refuse to tattoo people with HIV. Prisons have refused HIV neutral individuals access to their antiviral medications, causing them to fall ill and die. Your perceived fear of infection does not take seniority to people's safety. The reality is, we are all in charge of our own sexual health. It is not a person living with HIV's responsibility to disclose their status upfront when your express interest in them, it is also your responsibility to foster a conversation that promotes healthy sexual practices for all parties involved. It is everyone's responsibility to lead with kindness, understanding, and the knowledge that we must take the necessary steps to ensure our own wellbeing in sexual encounters especially when we are engaging in these encounters with strangers. We must have the empathy to understand that not everyone can share their status on their profiles. Undetectable means untransmittable. As a person living with HIV, I take care of my health because I love myself and I love my community enough to stop the spread of HIV. I urge other people in our community to do the same by getting on PREP if they're negative and by getting undetectable if they are positive. Don't reward those people with cruelty and make demands of them when you could take the steps to ensure your safety regardless of another persons status.

[specters]

i like going to pride not just to see other lgbt people but also because i love free shit 👍

[bisexualspace]

It's World AIDS Day so I wanted to run through a couple quick points

HIV is treatable! There's been incredible advancements in the treatment of HIV in the last few decades. Life expectancy for those living with HIV is the same as someone without the virus if they are on treatment.

U=U: If you're on treatment and your viral load is undetectable, you cannot transmit HIV to your partners.

PrEP is widely available. If you belong to a group that has an increased incidence of HIV transmission, you should be able to access Pre-Exposure Prophylaxis. Essentially this is a combination of two medications that is highly effective at preventing transmission of HIV. In some countries (such as the UK), you can access PrEP for free, however you can also source PrEP online in over 100 countries.

Knowledge is power. Knowing your status helps ensure you can access treatment early and prevent transmission to others. And remember, anyone who is sexually active can get HIV. Get tested regularly if you can

Anyways lets continue to destigmatise HIV, reduce transmission, and get everyone who needs it on treatment

[broadlyepi]

MMWR Booster #16: HIV Services and Outcomes During the COVID-19 Pandemic — United States, 2019–2021

Top 5 Takeaways

HIV Testing and PrEP Prescriptions Decreased Then Rebounded: In 2020, a decline in HIV testing and preexposure prophylaxis (PrEP) prescriptions was observed in the first half of the year, followed by a rebound.

Stable HIV Care and Treatment: Despite initial disruptions, the number of persons linked to HIV care, prescribed antiretroviral therapy (ART), and achieving viral load suppression remained stable.

Impact of COVID-19 Pandemic: The COVID-19 pandemic, leading to the closure of health care venues and loss of health insurance, significantly impacted HIV services.

Innovative Service Delivery Models Needed: The pandemic highlighted the need for alternative HIV service delivery models, including telehealth and nonclinical settings.

Resilience in HIV Prevention and Care System: Despite early disruptions, the system showed resilience with a return to pre-pandemic trends in PrEP prescriptions and maintenance of ART services.

Full summary link: BroadlyEpi.com

Enjoying these summaries? Check back every day at 8am and 4pm Pacific Time (UTC - 8) for a new MMWR Booster. A reblog would also be greatly appreciated, and thanks to everyone who already has! BroadlyEpi hopes to make Epidemiology and Public Health more approachable to anyone who's interested.